Research programme - cancer therapeutics - Artios Pharma

Drug Profile

Research programme - cancer therapeutics - Artios Pharma

Alternative Names: DDR - cancer therapeutics - Artios Pharma; Pol-theta

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator Cancer Research Technology
  • Developer Artios Pharma
  • Class
  • Mechanism of Action DNA repair enzyme modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 21 Sep 2016 Early research in Cancer in United Kingdom (unspecified route)
  • 21 Sep 2016 Artios in-licenses two lead DNA damage response programmes from Cancer Research Technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top